Skip to content

Efficacy and safety assessment of Centella asiatica as a herbal dietary supplement to reduce blood sugar levels in type 2 diabetes patients in Thailand

Efficacy and safety assessment of Centella asiatica as a herbal dietary supplement to reduce blood sugar levels in type 2 diabetes patients in Thailand

Status
Unknown
Phases
Phase 2Phase 3
Study type
Interventional
Source
TCTR
Registry ID
TCTR20221219003
Enrollment
80
Registered
2022-12-19
Start date
2022-12-06
Completion date
Unknown
Last updated
2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Adult patients with type II diabetes mellitus Diabetes Mellitus, Non-Insulin-Dependent

Interventions

Centella asiatica capsule,Placebo capsule
Experimental Drug,Placebo Comparator Drug

Sponsors

(in process) the Royal College of Physicians of Thailand
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1). Age 18-65 years 2). Willing to participate the study 3). Hemoglobin A1C >6.5% or fasting blood sugar >125 mg/dL

Exclusion criteria

Exclusion criteria: 1).Pregnancy or breastfeeding 2).Type I diabetes mellitus 3).Hypo- or hyperthyroidism 4).Severe hepatic diseases 5).Severe renal disease 6).Allergic to Centella asiatica 7).Currently treated with injected insulin

Design outcomes

Primary

MeasureTime frame
Hemoglobin A1C 12 weeks percent

Secondary

MeasureTime frame
Fasting blood sugar 12 weeks mg/dL,Cytokine (TNF-alpha, IFN-gamma, IL-4, IL-10) 12 weeks pg/mL,Liver function test (AST, ALT) 12 weeks IU/L,Serum creatinine 12 weeks mg/dL,Clinical adverse reactions 12 weeks Clinical adverse reactions,Lipid profile 12 weeks mg/dL

Countries

Thailand

Contacts

Public ContactWeeratian Tawanwongsri

Walailak University

weeratian.ta@gmail.com075673082

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 9, 2026